Quantumzyme Highlights Enzyme Engineering Platform and Ongoing Work in Sustainable Ibuprofen Synthesis
As part of its green chemistry initiatives, Quantumzyme has been evaluating enzyme-based methods to reduce the environmental footprint of common small molecule drug production. One area of focus has been the development of an enzyme-driven approach to ibuprofen synthesis. Ibuprofen, a widely used anti-inflammatory and pain relief medication, is typically produced through multi-step chemical processes that involve hazardous reagents and generate significant chemical waste.
'At Quantumzyme, we're exploring how computationally designed enzymes can be used to reimagine traditional chemical processes,' stated Naveen Kulkarni, CEO of Quantumzyme. 'While our work on ibuprofen synthesis continues to evolve, it illustrates the potential of enzyme catalysis to reduce complexity and environmental impact in pharmaceutical manufacturing.'
The company's enzyme discovery efforts center on its proprietary in silico platform, which integrates structural modeling, molecular docking, and virtual screening to identify enzymes with high specificity and stability for industrially relevant reactions. In the case of ibuprofen, Quantumzyme's team screened 22 candidate enzymes and identified a promising variant- bcPADH from Burkholderia cenocepacia- capable of converting a key intermediate (ibuprofen aldehyde) into the final active pharmaceutical ingredient under lab conditions.
By using bacterial systems to express and optimize this enzyme, the company has been able to achieve high conversion efficiency and purity, under safer, low-energy conditions. Importantly, this method avoids the use of harsh substances such as hydrofluoric acid, carbon monoxide, and pyrophoric metals commonly found in traditional synthesis routes.
While Quantumzyme's current research around ibuprofen is one application, the platform is being developed to support a wide range of use cases across pharmaceuticals, specialty chemicals, agrochemicals, and biofuels. The company's strategy focuses on applying green chemistry principles to reduce hazardous inputs, minimize waste, and improve process efficiency across sectors.
'This is about more than one molecule,' added Kulkarni. 'We're building a platform that can be applied broadly- wherever sustainable, precise biocatalysis can offer value over conventional chemistry.'
Quantumzyme continues to optimize its enzyme systems and evaluate potential commercial pathways for future deployment. We are presently assessing scale-up feasibility and industry integration for our enzyme-enabled solutions.
For the most current information and updates, please visit our website at www.quantumzymecorp.com.
About Quantumzyme Corp.
Quantumzyme Corp. is a pioneering biotransformation company revolutionizing chemical processes through sustainable, enzyme-based solutions. Specializing in green chemistry, it harnesses quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts that enhance efficiency, reduce waste, and minimize environmental impact. By integrating computational modeling with wet-lab validation, Quantumzyme delivers scalable, cost-effective biocatalysis solutions that improve industrial sustainability. Offering end-to-end enzyme development services- from discovery and engineering to process optimization and scale-up—Quantumzyme empowers its partners to adopt greener, more efficient production methods. Committed to sustainability and innovation, the company envisions a future where biotechnology drives global solutions for climate change, pollution, and resource efficiency, making eco-friendly biocatalysis the industry standard.
Disclaimer
The information contained in this press release is provided by Quantumzyme Corp. ('Quantumzyme') for general informational purposes only. This release may include forward-looking statements that reflect Quantumzyme's current expectations, estimates, projections, and assumptions about future events, business performance, market conditions, or technological developments. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. Forward-looking statements are based on management's beliefs and assumptions as of the date of this press release and are subject to change without notice.
Quantumzyme makes no representations or warranties, express or implied, regarding the accuracy, completeness, or reliability of the information contained herein. The company undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future developments, or changes in expectations, except as required by applicable law. Past performance should not be taken as an indicator of future results, and readers should not place undue reliance on any projections or expectations presented in this release.
This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities, nor does it provide financial, investment, or legal advice. Any references to market trends, scientific advancements, or industry insights are provided for contextual purposes only and should not be interpreted as endorsements, guarantees, or definitive predictions of future developments. Readers and investors are encouraged to conduct their own due diligence and seek independent professional advice before making any investment or business decisions related to Quantumzyme or its affiliates.
Media Contact:
Naveen Kulkarni
Chief Executive Officer
Quantumzyme Corp.
15656 Bernardo Center Drive, Suite 801
San Diego, CA 92127
Phone: +1 (858) 203-0312
Email: [email protected]
Website: www.quantumzymecorp.com
View the original release on www.newmediawire.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
10 hours ago
- Business Insider
Kepler Capital Remains a Buy on Sandoz Group Ltd (SDZXF)
In a report released on August 7, Nicolas Pauillac from Kepler Capital maintained a Buy rating on Sandoz Group Ltd, with a price target of CHF42.60. The company's shares closed yesterday at $58.24. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Pauillac covers the Healthcare sector, focusing on stocks such as Sanofi, Formycon AG, and COSMO Pharmaceuticals N.V.. According to TipRanks, Pauillac has an average return of 11.7% and a 48.15% success rate on recommended stocks. In addition to Kepler Capital , Sandoz Group Ltd also received a Buy from Barclays's Emily Field in a report issued yesterday. However, on the same day, Jefferies downgraded Sandoz Group Ltd (Other OTC: SDZXF) to a Hold. SDZXF market cap is currently $24.67B and has a P/E ratio of 107.75.
Yahoo
11 hours ago
- Yahoo
Why Investors Were so High on Curaleaf Stock Thursday
Key Points As is common in the pot industry, Curaleaf posted a net loss in its second quarter. There were several reasons to be optimistic about its future, however. 10 stocks we like better than Curaleaf › Earnings season is always something of a nerve-shredding time for marijuana stock investors, as pot companies more often than not tend to post bottom-line losses. Sure enough, sector mainstay Curaleaf (OTC: CURLF) delivered a deficit in the second quarter, as its earnings release published after market close Wednesday revealed. However, it wasn't significantly deeper on a comparable basis. Meanwhile, there were other glimmers of hope in the document. As a result, bullish investors traded up Curaleaf stock on the day, powering it to a nearly 7% gain. Investor tolerance for loss For the quarter, Curaleaf posted total net revenue of more than $314 million, representing a slide from the over $342 million it earned in the same period of 2024. That net loss, meanwhile, was considerable but not much worse than in the year-ago frame; it deepened to $53 million ($0.07 per share) from nearly $49 million. Curaleaf continued to expand during the quarter, as it flicked the lights on in two dispensaries, one located in populous Florida (specifically the municipality of Winter Park, near Orlando) and the other in Lima, Ohio. On the product side, it launched a pair of new products, Anthem pre-rolled cannabis cigarettes and Select ACE oil. Perhaps more impactfully for the future, it was awarded a license to participate in the specialized marijuana market of another populous location, the country of Turkey. Its license gives it entry to that nation's medical pot market, which began at the end of July with a new law allowing for sales in pharmacies to qualifying patients. Looking for legalization As ever with marijuana stocks, they're probably not going to move significantly -- and sustainably -- until full-blown legalization (or at least decriminalization) is enacted in a major jurisdiction. All eyes are on the U.S., where halting efforts in this sphere have resulted in a patchwork of states where medical and/or recreational weed sale and consumption are permitted. Should you invest $1,000 in Curaleaf right now? Before you buy stock in Curaleaf, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Curaleaf wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $635,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,099,758!* Now, it's worth noting Stock Advisor's total average return is 1,046% — a market-crushing outperformance compared to 181% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Investors Were so High on Curaleaf Stock Thursday was originally published by The Motley Fool Sign in to access your portfolio
Business Upturn
16 hours ago
- Business Upturn
Earth Science Tech, Inc. Reports 61% Asset Growth to $7.69 Million and $8.7 Million in First Quarter Revenue Following Foundational Quarter of Strategic Acquisitions
MIAMI, FL, Aug. 08, 2025 (GLOBE NEWSWIRE) — MIAMI, FL – August 8, 2025 – Earth Science Tech, Inc. (OTC: ETST) ('ETST' or the 'Company'), a strategic holding company focused on acquiring and scaling high-potential operating businesses, today announced its financial and operational results for the first fiscal quarter ended June 30, 2025. Giorgio R. Saumat, ETST's CEO, commented: 'The first quarter of fiscal 2025 was a pivotal period for Earth Science Tech. We strategically deployed capital to acquire high-potential operating businesses that are now poised to enhance our diversified product and service offerings. This was a foundational quarter, setting the stage for the future. Our focus has now firmly shifted from acquisitions to maximizing the value and profitability of our current divisions, ensuring we capitalize on these strategic investments for our shareholders throughout the remainder of the fiscal year.' First Quarter Fiscal 2025 Financial Highlights Total Assets: Increased by 61% to $7.69 million as of June 30, 2025, up from $4.77 million in the prior-year period. Increased by 61% to $7.69 million as of June 30, 2025, up from $4.77 million in the prior-year period. Revenue: Generated $8.7 million as of June 30, 2025, an increase from $8.5 million in the prior-year period. Generated $8.7 million as of June 30, 2025, an increase from $8.5 million in the prior-year period. Shareholder Value: Reduced total common shares outstanding by 4.78% to 294,297,607 as of June 30, 2025, down from 309,067,711 shares in the prior-year period. Reduced total common shares outstanding by 4.78% to 294,297,607 as of June 30, 2025, down from 309,067,711 shares in the prior-year period. Cash Position: Reported cash and cash equivalents of $0.88 million. The decrease from $1.38 million in the prior-year period is a direct result of the strategic deployment of capital to fund key acquisitions. Strategic and Operational Update During the first quarter, ETST executed its growth strategy by investing in and acquiring a portfolio of operating businesses: Healthcare Expansion: Acquired 100% of Las Villas Health Care, Inc., a Coral Gables-based wellness center, and DOConsultation, LLC, a telehealth company. Acquired 100% of Las Villas Health Care, Inc., a Coral Gables-based wellness center, and DOConsultation, LLC, a telehealth company. Direct-to-Consumer Brands: Secured 80% ownership of Magnefuse, LLC, and Alicat, LLC (the 'MagneChef Portfolio'), DTC brands with a portfolio of unique patents and intellectual property. Secured 80% ownership of Magnefuse, LLC, and Alicat, LLC (the 'MagneChef Portfolio'), DTC brands with a portfolio of unique patents and intellectual property. Operational Infrastructure: Established a new customer service center in Doral, FL, to centralize support operations across all ETST divisions. Subsequent to the quarter's end, the Company has continued to execute on its operational goals: Enhanced Compliance: Joined the OTCID Tier on the OTC Markets, providing enhanced disclosure and transparency for investors. Joined the OTCID Tier on the OTC Markets, providing enhanced disclosure and transparency for investors. Compounding Pharmacy Expansion: The Company's MisterMeds, LLC division is now fully staffed and operational, actively dispensing in Texas and securing new accounts. The Company's MisterMeds, LLC division is now fully staffed and operational, actively dispensing in Texas and securing new accounts. Real Estate Development: Avenvi, LLC, an ETST division, has broken ground on its first residential development, with the project progressing on schedule. About Earth Science Tech, Inc. Earth Science Tech, Inc. operates as a strategic holding company, focused on value creation through the acquisition, operational optimization, and management of its operating businesses. The Company's current operations include compounding pharmaceuticals, telemedicine and real estate development through its wholly owned subsidiaries: LLC, Peaks Curative, LLC, Avenvi, LLC, Mister Meds, LLC ('Mister Meds'), and Earth Science Foundation, Inc., Las Villas Health Care, Inc., DOConsultations, LLC., and an 80% interest in MagneChef. To learn more, please visit: LLC. based in Miami, Florida, is a fully licensed compounding pharmacy authorized to fulfill prescriptions in the following states and territories: Arizona, Colorado, Delaware, Florida, Georgia, Illinois, Indiana, Iowa, Maine, Maryland, Minnesota, Missouri, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Rhode Island, Utah, Wisconsin and Puerto Rico. RxCompound is actively pursuing licensure in the remaining U.S. states. To learn more please visit: MisterMeds, LLC. Mister Meds, acquired on October 1, 2024, is in Abilene, Texas. The pharmacy received full compounding licensure in March 2025. It operates out of a 5,000 sq. ft. facility owned by Avenvi and includes advanced sterile compounding capabilities with both positive and negative pressure environments, as well as hazardous drug handling. Mister Meds is currently applying for licensure in states not yet serviced by RxCompound. To learn more please visit: Peaks Curative, LLC. Peaks is a telemedicine referral platform offering asynchronous consultations for Peaks-branded compounded medications prepared at RxCompound and Mister Meds. The platform operates in states where either pharmacy is licensed. Through the development of its own healthcare provider network, and ongoing licensure expansion for both pharmacies, Peaks aims to offer services nationwide. In addition, the company has recently expanded into the veterinary market through the acquisition of To learn more please visit: Las Villas Health Care, Inc. Las Villas is a brick-and-mortar healthcare facility dedicated to the Spanish speaking community. Our expert-led services include advanced sexual health treatments, and customized solutions to enhance physical performance. We combine compassionate, personalized care with clear, trustworthy education—empowering you to take control of your health with confidence. To learn more please visit: LLC. Doconsultation was born with a passion to modernize the availability and delivery of home therapies. DOConsultations providers tailor a medication plan around your health and wellness goals and follow up with our patients to ensure results, while our partner pharmacies conveniently ship directly to your door. To learn more please visit: Avenvi, LLC. Avenvi is a diversified real estate company engaged in development, asset management, and financing. With a growing portfolio of real estate holdings, Avenvi provides turnkey solutions from development to end-user financing. It also manages investment activities for ETST and oversees the Company's ongoing $5 million share repurchase program. To learn more please visit: MagneChef MagneChef is a direct-to-consumer retail brand. Utilizing its patents and intellectual properties, the company aims to develop new products that can be marketed and sold online. Currently, the company has developed products for cooking. MagneChef is in the process of expanding its product line for new offerings that incorporate its intellectual property. To learn more please visit: About Earth Science Foundation, Inc. Earth Science Foundation Inc. a 501(c)(3) nonprofit organization incorporated on February 11, 2019, is the charitable arm of ETST. ESF accepts grants and donations to assist individuals who need financial support for prescription costs at both RxCompound and Mister Meds. SAFE HARBOR ACT: Forward-Looking Statements. Except for historical information, the matters discussed herein may be considered 'forward-looking' statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including, without limitation, future-oriented statements related to cash flow, gross margins, revenues, and expenses. These statements are based on and reflect our current expectations, estimates, assumptions and/or projections, our perception of historical trends and current conditions, as well as other factors that we believe are appropriate and reasonable under the circumstances. Forward-looking statements generally can be identified by the fact that they do not relate strictly to historical or current facts. They may include forward-looking words such as 'expect,' 'expectation,' 'believe,' 'anticipate,' 'may,' 'could,' 'intend,' 'belief,' 'plan,' 'estimate,' 'target,' 'predict,' 'likely,' 'seek,' 'project,' 'model,' 'ongoing,' 'will,' 'should,' 'forecast,' 'outlook' or similar terminology. Forward-looking statements are subject to a number of risks and uncertainties that may cause the Company's actual results to differ materially from our intent, belief or current expectations, including, inter alia, the markets for the Company's products and services, costs of goods and services, other expenses, government regulations, litigations, and general business conditions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, estimated or projected. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law. Company Contact:Giorgio R. SaumatCEO and Chairman of the Board(305) 724-5684 [email protected]
